Rev Fac Cien Med Univ Nac Cordoba. 2026 Mar 30;83(1):e49234. doi: 10.31053/1853.0605.v83.n1.49234.
ABSTRACT
INTRODUCTION: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab.
CASE PRESENTATION: We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence.
CONCLUSION: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies.
PMID:41911202 | DOI:10.31053/1853.0605.v83.n1.49234